While improving patient outcomes, PARP inhibitors are associated with additional costs that are significantly higher than generic options (e.g., docetaxel or abiraterone) or even non-generic options (enzalutamide) and contribute to the ever-growing economic burden of PCa. The gene discussed is PARP1; the disease is posterior cortical atrophy.